

Robert G Maki

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7110627/robert-g-maki-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

429
papers

35,978
citations

93
h-index

186
g-index

477
ext. papers

41,358
ext. citations

6.1
avg, IF

6.72
L-index

#	Paper	IF	Citations
429	Impact of Intraoperative Molecular Imaging after Fluorescent-Guided Pulmonary Metastasectomy for Sarcoma.. <i>Journal of the American College of Surgeons</i> , 2022 , 234, 748-758	4.4	2
428	SELNET clinical practice guidelines for bone sarcoma.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 174, 103685	7	0
427	Adult Pleomorphic Rhabdomyosarcomas: Assessing Outcomes Associated with Radiotherapy and Chemotherapy Use in the National Cancer Database. <i>Sarcoma</i> , 2021 , 2021, 9712070	3.1	
426	A randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS11583-TPS11583	2.2	0
425	Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. <i>Journal of Clinical Oncology</i> , 2021 , JCO2003452	2.2	1
424	Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	1
423	Surgical Management of Sarcoma Metastatic to Liver. <i>Surgical Oncology Clinics of North America</i> , 2021 , 30, 57-67	2.7	2
422	Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. <i>Future Oncology</i> , 2020 , 16, 4289-4301	3.6	6
421	A framework for advancing our understanding of cancer-associated fibroblasts. <i>Nature Reviews Cancer</i> , 2020 , 20, 174-186	31.3	790
420	Multiplexed Evaluation of Microdosed Antineoplastic Agents in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2020 , 26, 3958-3968	12.9	7
419	Follicular dendritic cell sarcoma and its response to immune checkpoint inhibitors nivolumab and ipilimumab. <i>BMJ Case Reports</i> , 2020 , 13,	0.9	6
418	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1081	2.2	48
417	Utility of immune checkpoint inhibitors (ICI) in 3 patients (pts) with sarcomas of antigen presenting cells (follicular dendritic cell sarcoma [FDSC], histiocytic sarcoma [HS]).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e23574-e23574	2.2	0
416	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. <i>European Journal of Cancer</i> , 2020 , 127, 96-107	7.5	108
415	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. <i>Oncologist</i> , 2020 , 25, e1562-e1573	5.7	3
414	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. <i>Annals of Oncology</i> , 2020 , 31, 1506-1517	10.3	39
413	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. <i>Oncologist</i> , 2020 , 25, e1655-e1662	5.7	5

412	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020 , 126, 98-104	6.4	14
411	Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. <i>Oncolmmunology</i> , 2020 , 9, 1747340	7.2	49
410	Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2019 , 120, 132-139	7.5	12
409	An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. <i>Nature Cell Biology</i> , 2019 , 21, 203-213	23.4	19
408	Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. <i>BMC Cancer</i> , 2019 , 19, 593	4.8	9
407	An unusual case of Kaposi sarcoma masquerading as cystitis in a kidney transplant recipient. <i>Transplant Infectious Disease</i> , 2019 , 21, e13132	2.7	4
406	Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. <i>Cancer</i> , 2019 , 125, 2610-2620	6.4	23
405	Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. <i>British Journal of Cancer</i> , 2019 , 120, 1026-1032	8.7	12
404	Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. <i>Lancet Oncology, The</i> , 2019 , 20, 877-886	21.7	34
403	A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. <i>Cancer</i> , 2019 , 125, 2445-2454	6.4	9
402	Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1424-1431	2.2	93
401	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. <i>Modern Pathology</i> , 2019 , 32, 1772-1785	9.8	33
400	Novel fusion gene in aggressive angiomyxoma. <i>BMJ Case Reports</i> , 2019 , 12,	0.9	8
399	Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. <i>Scientific Reports</i> , 2019 , 9, 14551	4.9	16
398	Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. <i>Cancer</i> , 2019 , 125, 4435-4441	6.4	7
397	Sarcomas 2019 , 214-220		1
396	Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS). <i>Annals of Oncology</i> , 2019 , 30, v683 ^{10.3}		13
395	Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11015-11015	2.2	31

394	First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), □ cemiplimab in patients (pts) with advanced malignancies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2508-2508	2.2	16
393	Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints: A Study Based on a Multicenter-Pooled Database of 31 International Sarcoma Centers. <i>Journal of Bone and Joint Surgery - Series A</i> , 2019 , 101, 1309-1318	5.6	12
392	A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. <i>Oncologist</i> , 2019 , 24, 857-863	5.7	11
391	Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review. <i>JAMA Oncology</i> , 2019 , 5, 254-260	13.4	42
390	Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Oncology</i> , 2018 , 29, 857-871	10.3	32
389	Sarcoma. <i>Practical Guides in Radiation Oncology</i> , 2018 , 347-367	0	1
388	TERT promoter mutations in solitary fibrous tumour. <i>Histopathology</i> , 2018 , 73, 843-851	7.3	22
387	Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. <i>Annals of Oncology</i> , 2018 , 29, 1995-2002	10.3	22
386	A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARCO24 study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11505-11505	2.2	2
385	TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS11590-TPS11590	2.2	1
384	A comparison of three clinical factors as predictive markers for response to immunotherapy in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21158-e21158	2.2	
383	Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e23570-e23570	2.2	
382	Whole exome sequencing (WES) of metastatic leiomyosarcoma (LMS) and liposarcoma (LPS) and correlation of genomic aberrations with clinical outcomes in the phase III randomized trial of trabectedin (T) vs. dacarbazine (D).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11513-11513	2.2	
381	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018 , 23, 62-70	5.7	42
380	Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment. <i>Journal of Clinical Oncology</i> , 2018 , 36, 194-201	2.2	26
379	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1020-1044	2.2	83
378	Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition. <i>Journal of Clinical Oncology</i> , 2018 , 36, 210-216	2.2	46
377	Sarcoma: The Merging of Science and Clinical Care. <i>Journal of Clinical Oncology</i> , 2018 , 36, 99-100	2.2	3

376	Sorafenib for Advanced and Refractory Desmoid Tumors. <i>New England Journal of Medicine</i> , 2018 , 379, 2417-2428	59.2	155
375	Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, e184060	13.4	54
374	A Method to Summarize Toxicity in Cancer Randomized Clinical Trials. <i>Clinical Cancer Research</i> , 2018 , 24, 4968-4975	12.9	8
373	Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. <i>JAMA Oncology</i> , 2017 , 3, 944-952	13.4	49
372	Treatment of soft tissue sarcoma: a focus on earlier stages. <i>Future Oncology</i> , 2017 , 13, 13-21	3.6	12
371	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2017 , 18, 1493-1501	21.7	544
370	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3433-3439	2.2	77
369	Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. <i>Annals of Oncology</i> , 2017 , 28, 2595-2605	10.3	139
368	Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. <i>Modern Pathology</i> , 2017 , 30, 1433-1442	9.8	152
367	Targeting sarcoma tumor-initiating cells through differentiation therapy. <i>Stem Cell Research</i> , 2017 , 21, 117-123	1.6	8
366	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. <i>Cell</i> , 2017 , 171, 950-965.e28	56.2	451
365	Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. <i>Gynecologic Oncology</i> , 2017 , 146, 531-537	4.9	35
364	Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11001-11001	2.2	20
363	A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11003-11003	2.2	22
362	Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11008-11008	2.2	27
361	Extended treatment with adjuvant imatinib (IM) for patients (pts) with high-risk primary gastrointestinal stromal tumor (GIST): The PERSIST-5 study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11009-11009	2.2	8
360	Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS11081-TPS11081	2.2	4
359	Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 60-60	2.2	1

358	Gastrointestinal Stromal Tumor 2017 , 523-529		5
357	Introduction to Soft Tissue Sarcoma 2017 , 489-497		0
356	Sarcoma tumor size (T) staging: Are radiology or pathology measurements more appropriate?. <i>Journal of Clinical Oncology</i> , 2017 , 35, e22522-e22522	2.2	
355	Safety and efficacy of trabectedin when administered in the inpatient vs. outpatient setting in a subset analysis of a phase III randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e22516-e22516	2.2	26
354	Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 786-93	2.2	466
353	Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy. <i>Gastroenterology Clinics of North America</i> , 2016 , 45, 477-86	4.4	4
352	PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3898-3905	2.2	107
351	Development and clinical application of an integrative genomic approach to personalized cancer therapy. <i>Genome Medicine</i> , 2016 , 8, 62	14.4	58
350	Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches. <i>Oncology and Therapy</i> , 2016 , 4, 1-16	2.7	2
349	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 1629-37	4.0	445
348	Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 501-512	3.8	3
347	Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028A multicenter phase II study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11006-11006	2.2	32
346	A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11016-11016	2.2	13
345	Pegylated liposomal doxorubicin (PLD) as an active treatment option for desmoid tumor (DT) patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11032-11032	2.2	3
344	Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11037-11037	2.2	5
343	Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11061-11061	2.2	4
342	Efficacy of sorafenib in patients with desmoid-type fibromatosis.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11065-11065	2.2	7
341	In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3086-3086	2.2	2

340	Epithelioid Sarcoma 2016 , 237-241	0
339	Extraskeletal Osteogenic Sarcoma 2016 , 327-334	1
338	Gastrointestinal Stromal Tumors 2016 , 77-104	1
337	Undifferentiated Pleomorphic Sarcoma (UPS) (Malignant Fibrous Histiocytoma (MFH) and Myxofibrosarcoma) 2016 , 143-152	2
336	Leiomyosarcoma 2016 , 125-142	0
335	Sarcomas More Common in Children 2016 , 243-274	
334	Malignant Peripheral Nerve Sheath Tumor (MPNST) and Triton Tumor 2016 , 165-176	
333	Radiation-Induced Sarcoma 2016 , 275-281	
332	Desmoid Tumor/Deep-Seated Fibromatosis (Desmoid-Type Fibromatosis) 2016 , 177-194	
331	Uncommon/Unique Sites 2016 , 343-351	1
330	Solitary Fibrous Tumor/Hemangiopericytoma 2016 , 195-201	
329	Extraskeletal Myxoid Chondrosarcoma 2016 , 307-313	
328	Liposarcoma 2016 , 105-124	
327	Other Uterine Sarcomas 2016 , 315-326	
326	Reactive Lesions 2016 , 387-390	
325	General Description 2016 , 3-17	0
324	Natural History: Importance of Size, Site, Histopathology 2016 , 19-40	
323	Desmoplastic Small Round Cell Tumor 2016 , 299-305	

322	General Statement as to Efficacy of Surgery, Chemotherapy, Radiation Therapy, and Immunotherapy 2016 , 41-74		
321	Sustentacular Tumors of Lymph Tissue 2016 , 335-341		
320	Synovial Sarcoma 2016 , 153-163		
319	Clear Cell Sarcoma/Melanoma of Soft Parts 2016 , 291-297		
318	Alveolar Soft Part Sarcoma 2016 , 283-289		1
317	Vascular Sarcomas 2016 , 221-236		
316	Visualizing toxicity: A single score to summarize toxicity in randomized clinical trials.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6605-6605	2.2	
315	Management of Soft Tissue Sarcoma 2016 ,		7
314	Fibrosarcoma and Its Variants 2016 , 203-219		
313	Mostly Benign/Rarely Metastasizing 2016 , 355-367		
312	Selected Benign Tumors 2016 , 369-386		
311	Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults: A Review. <i>JAMA Oncology</i> , 2016 , 2, 941-7	13.4	18
310	Perspectives for immunotherapy in endocrine cancer. <i>Endocrine-Related Cancer</i> , 2016 , 23, R469-84	5.7	10
309	Monogenic and polygenic determinants of sarcoma risk: an international genetic study. <i>Lancet Oncology, The</i> , 2016 , 17, 1261-71	21.7	121
308	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. <i>Oncologist</i> , 2015 , 20, 823-30	5.7	23
307	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. <i>European Journal of Cancer</i> , 2015 , 51, 852-60	7.5	21
306	GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1849-54		36
305	Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation. <i>Clinical Sarcoma Research</i> , 2015 , 5, 21	2.5	3

304	Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. <i>European Journal of Cancer</i> , 2015 , 51, 2413-22	7.5	59
303	Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. <i>European Journal of Cancer</i> , 2015 , 51, 210-7	7.5	67
302	Sarcomas. <i>Pediatric Clinics of North America</i> , 2015 , 62, 179-200	3.6	42
301	3403 Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS). <i>European Journal of Cancer</i> , 2015 , 51, S689	7.5	3
300	Psychological Distress of Internal Medicine Residents Rotating on a Hematology and Oncology Ward: An Exploratory Study of Patient Deaths, Personal Stress, and Attributed Meaning. <i>Medical Science Educator</i> , 2015 , 25, 413-420	0.7	4
299	Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma. <i>Rare Tumors</i> , 2015 , 7, 5992	1.1	24
298	Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy. <i>Frontiers in Oncology</i> , 2015 , 5, 186	5.3	24
297	Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. <i>Sarcoma</i> , 2015 , 2015, 532478	3.1	43
296	Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. <i>Oncologist</i> , 2015 , 20, 433-9	5.7	41
295	Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. <i>European Journal of Cancer</i> , 2015 , 51, 1611-7	7.5	48
294	A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10503-10503	2.2	10
293	The somatic mutational landscape in soft tissue sarcoma: Early results from TCGA data.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10508-10508	2.2	2
292	A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10514-10514	2.2	3
291	Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year interim analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10537-10537	2.2	2
290	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. <i>Journal of Clinical Oncology</i> , 2015 , 33, LBA10502-LBA10502	2.2	16
289	SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS10578-TPS10578	2.2	11
288	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. <i>Journal of Clinical Oncology</i> , 2015 , 33, LBA10502-LBA10502	2.2	16
287	Imatinib mesylate (IM) activity in patients (pts) with locally advanced tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10561-10561	2.2	

286	A study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS10577-TPS10577	2.2	1
285	International expert opinion on patient-tailored management of soft tissue sarcomas. <i>European Journal of Cancer</i> , 2014 , 50, 679-89	7.5	30
284	Patient-derived xenografts for individualized care in advanced sarcoma. <i>Cancer</i> , 2014 , 120, 2006-15	6.4	118
283	Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1563-70	2.2	192
282	Consumptive coagulopathy in angiosarcoma: a recurrent phenomenon?. <i>Sarcoma</i> , 2014 , 2014, 617102	3.1	11
281	The mechanistic target of rapamycin pathway in sarcomas: from biology to therapy. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 653-664	1.1	
280	A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. <i>Cancer</i> , 2014 , 120, 2448-56	6.4	133
279	Malignant peripheral nerve sheath tumors. <i>Oncologist</i> , 2014 , 19, 193-201	5.7	186
278	Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014 , 37, 528-34	2.7	26
277	Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10508-10508	2.2	7
276	Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10520-10520	2.2	11
275	Stress and empathy among internal medicine trainees on an inpatient hematology-oncology ward.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 231-231	2.2	1
274	Sarcomas of Soft Tissue 2014 , 1753-1791.e10		3
273	Management of Soft Tissue Sarcoma 2013 ,		29
272	Toward better soft tissue sarcoma staging: building on american joint committee on cancer staging systems versions 6 and 7. <i>Annals of Surgical Oncology</i> , 2013 , 20, 3377-83	3.1	41
271	Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series. <i>Targeted Oncology</i> , 2013 , 8, 211-213	5	39
270	Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2013 , 14, 371-82	21.7	152
269	Advanced chondrosarcomas: role of chemotherapy and survival. <i>Annals of Oncology</i> , 2013 , 24, 2916-22	10.3	142

268 General Description **2013**, 1-17

267 Angiosarcomas and other sarcomas of endothelial origin. *Hematology/Oncology Clinics of North America*, **2013**, 27, 975-88 3.1 27

266 When Benign Tumors Mimic Malignancies: A Case of Lymphangiomatosis Masquerading as Metastatic Disease. *Rare Cancers and Therapy*, **2013**, 1, 21-27 2

265 Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications. *Targeted Oncology*, **2013**, 8, 295-300 5 9

264 Malignant Peripheral Nerve Sheath Tumor (MPNST) and Triton Tumor **2013**, 149-160 1

263 Synovial Sarcoma **2013**, 137-147

262 Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet, The*, **2013**, 381, 295-302 4.0 908

261 Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. *Leukemia Research*, **2013**, 37, 790-4 2.7 16

260 Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. *Annals of Oncology*, **2013**, 24, 537-542 10.3 31

259 Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer. *Frontiers in Oncology*, **2013**, 3, 9 5.3 7

258 Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival. *Annals of Oncology*, **2013**, 24, 1924-1930 10.3 34

257 Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. *Annals of Surgery*, **2013**, 258, 422-9 7.8 125

256 Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. *Annals of Oncology*, **2013**, 24, 252-7 10.3 80

255 A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. *Sarcoma*, **2013**, 2013, 168145 3.1 114

254 Solitary Fibrous Tumor/Hemangiopericytoma **2013**, 179-184 2

253 Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). *Cancer*, **2013**, 119, 1555-61 6.4 122

252 Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. *British Journal of Cancer*, **2013**, 109, 1717-24 8.7 49

251 Preliminary results of high-dose single-fraction radiotherapy for the management of chordomas of the spine and sacrum. *Neurosurgery*, **2013**, 73, 673-80; discussion 680 3.2 62

250	Abstract LB-295: Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenibvsplacebo in TKI-refractory metastatic GIST. 2013 ,		4
249	Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10503-10503	2.2	20
248	Phase Ib study of RG7112 with doxorubicin (D) in advanced soft tissue sarcoma (ASTS).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10514-10514	2.2	13
247	A model for multi-institutional, multidisciplinary sarcoma videoconferencing.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10521-10521	2.2	2
246	Demonstration of gender-specific variability in a pharmacokinetic (PK) analysis of the PERSIST-5 trial of adjuvant imatinib (IM) for patients with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10538-10538	2.2	1
245	Desmoplastic Small Round Cell Tumor 2013 , 275-280		
244	Alveolar Soft Part Sarcoma 2013 , 259-265		
243	Reactive Lesions 2013 , 355-358		
242	Desmoid Tumor/Deep-Seated Fibromatosis (Desmoid-Type Fibromatosis) 2013 , 161-177		
241	Gastrointestinal Stromal Tumors (GISTs) 2013 , 67-91		
240	Sarcomas More Common in Children 2013 , 221-250		0
239	Natural History: Importance of Size, Site, and Histopathology 2013 , 19-35		0
238	Epithelioid Sarcoma 2013 , 215-219		
237	Fibrosarcoma and Its Variants 2013 , 185-200		
236	Benign Soft Tissue Tumors 2013 , 339-354		
235	Other Uterine Sarcomas 2013 , 289-299		
234	Extraskeletal Myxoid Chondrosarcoma 2013 , 281-287		
233	Vascular Sarcomas 2013 , 201-213		

232 Uncommon/Unique Sites **2013**, 317-326

231 Mostly Benign/Rarely Metastasizing Soft Tissue Tumor **2013**, 329-337

230 Clear Cell Sarcoma/Melanoma of Soft Parts **2013**, 267-273

1

229 Extraskeletal Osteogenic Sarcoma **2013**, 301-307

228 Radiation-Induced Sarcomas **2013**, 251-257

227 Undifferentiated Pleomorphic Sarcoma (UPS; Malignant Fibrous Histiocytoma: MFH) and Myxofibrosarcoma **2013**, 129-136

1

226 General Statement as to Efficacy of Surgery/Chemotherapy/Radiation Therapy **2013**, 37-64

1

225 Sustentacular Tumors of Lymph Tissue **2013**, 309-315

224 Liposarcoma **2013**, 93-111

223 Uterine Sarcomas in the Elderly **2013**, 319-348

222 Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics.. *Journal of Clinical Oncology*, **2013**, 31, 10551-10551

2.2 1

221 Linking kinases to adverse events through kinase inhibitors.. *Journal of Clinical Oncology*, **2013**, 31, e13524-e13524

220 Leiomyosarcoma **2013**, 113-127

1

219 Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. *Journal of the American College of Surgeons*, **2012**, 215, 53-9; discussion 59-60

4.4 108

218 Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. *Annals of Surgical Oncology*, **2012**, 19, 1551-9

3.1 53

217 CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers. *Genes Chromosomes and Cancer*, **2012**, 51, 186-95

5 14

216 High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. *Genes Chromosomes and Cancer*, **2012**, 51, 207-18

5 229

215 The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. *Genes Chromosomes and Cancer*, **2012**, 51, 569-78

5 83

214	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. <i>Cancer</i> , 2012 , 118, 1649-55	6.4	171
213	New strategies in sarcoma therapy: linking biology and novel agents. <i>Clinical Cancer Research</i> , 2012 , 18, 5837-44	12.9	8
212	A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. <i>European Journal of Cancer</i> , 2012 , 48, 3036-44	7.5	105
211	Treatment of adult soft tissue sarcoma: old concepts, new insights, and potential for drug discovery. <i>Cancer Investigation</i> , 2012 , 30, 300-8	2.1	9
210	First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study. <i>European Journal of Cancer</i> , 2012 , 48, 547-63	7.5	55
209	The rule of fives, a simple way to stratify risk for primary gastrointestinal stromal tumors (GIST). <i>Clinical Sarcoma Research</i> , 2012 , 2, 21	2.5	5
208	Clinical Benefit with Regorafenib Across Subgroups and Post-Progression in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) After Progression on Imatinib (IM) and Sunitinib (SU): Phase 3 Grid Trial Update. <i>Annals of Oncology</i> , 2012 , 23, ix478-ix479	10.3	2
207	Targeted therapy in sarcoma: should we be lumpers or splitters?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 652-7	7.1	2
206	Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. <i>Cancer</i> , 2012 , 118, 3330-6	6.4	97
205	Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. <i>Cancer</i> , 2012 , 118, 5878-87	6.4	82
204	A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. <i>Investigational New Drugs</i> , 2012 , 30, 1193-202	4.3	63
203	Squamous cell carcinoma of the oral tongue in two patients previously exposed to long-term pegylated liposomal doxorubicin. <i>Oncologist</i> , 2012 , 17, 1594-5	5.7	11
202	A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. <i>Annals of Oncology</i> , 2012 , 23, 1335-1340	10.3	41
201	Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy. <i>Annals of Oncology</i> , 2012 , 23, 2205-2206	10.3	18
200	Randomization and statistical power: paramount in trial reproducibility (even for rare cancers). <i>Oncologist</i> , 2012 , 17, 1129-32	5.7	1
199	The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. <i>Clinical Cancer Research</i> , 2012 , 18, 2638-47	12.9	76
198	Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. <i>Annals of Oncology</i> , 2012 , 23, 1601-7	10.3	84
197	Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series. <i>Annals of Oncology</i> , 2012 , 23, 804-805	10.3	5

196	New therapeutic targets in soft tissue sarcoma. <i>Advances in Anatomic Pathology</i> , 2012 , 19, 170-80	5.1	43
195	A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (-) bone and soft tissue sarcomas (STS).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10003-10003	2.2	5
194	Optimizing the therapy of desmoplastic small round cell tumor: Combined experience from the two major cancer centers.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10021-10021	2.2	1
193	A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e13600-e13600	2.2	18
192	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA10008-LBA10008	2.2	1
191	Randomized multicenter double-blind phase II trial: The immunological adjuvant OPT-821 with or without a trivalent ganglioside vaccine in metastatic sarcoma patients following metastasectomy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS10103-TPS10103	2.2	1
190	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA10008-LBA10008	2.2	9
189	Genome-wide analysis and characterization of an online sarcoma cohort.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10097-10097	2.2	
188	Tenosynovial giant cell tumor (TGCT)/pigmented villonodular synovitis (PVNS): Outcome of 313 patients before the era of kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10022-10022	2.2	
187	How well do we communicate risk? An evaluation of AJCC version 6 and 7 staging systems for soft tissue sarcomas.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10001-10001	2.2	
186	Growth modulation index (GMI) as a metric of clinical benefit assessment among advanced soft tissue sarcoma (ASTS) patients receiving trabectedin as salvage therapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10013-10013	2.2	
185	Advanced soft-tissue sarcoma in patients over age 75: Patterns of care and survival.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10057-10057	2.2	
184	Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. <i>European Journal of Cancer</i> , 2011 , 47, 1006-12	7.5	77
183	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. <i>Lancet Oncology</i> , 2011 , 12, 1004-12	21.7	732
182	Eribulin in soft-tissue sarcomas. <i>Lancet Oncology</i> , 2011 , 12, 988-9	21.7	5
181	Advances in sarcoma genomics and new therapeutic targets. <i>Nature Reviews Cancer</i> , 2011 , 11, 541-57	31.3	291
180	Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. <i>Annals of Surgical Oncology</i> , 2011 , 18, 328-36	3.1	57
179	Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67 Suppl 1, S25-43	3.5	65

178	Chemotherapy in clear cell sarcoma. <i>Medical Oncology</i> , 2011 , 28, 859-63	3.7	47
177	Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 25-33	5	235
176	A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 644-53	5	341
175	Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab. <i>Journal of Clinical Oncology</i> , 2011 , 29, e638-40	2.2	5
174	Activity of Sorafenib against desmoid tumor/deep fibromatosis. <i>Clinical Cancer Research</i> , 2011 , 17, 4082-90	2.2	191
173	Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 942-6	8.9	354
172	R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4541-7	2.2	257
171	Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 10000-10000	2.2	9
170	Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 10009-10009	2.2	42
169	Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 10044-10044	2.2	3
168	Metastatic epithelioid hemangioendothelioma (EHE): Role of systemic therapy and survival.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 10079-10079	2.2	5
167	Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2501-2501	2.2	77
166	Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3039-3039	2.2	5
165	Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST).. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4-4	2.2	8
164	Comments regarding lung metastasis surgery for sarcoma. <i>Oncology</i> , 2011 , 25, 1210-1	1.8	
163	ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. <i>Nature</i> , 2010 , 467, 849-53	50.4	229
162	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. <i>Nature Genetics</i> , 2010 , 42, 715-21	36.3	521
161	Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. <i>New England Journal of Medicine</i> , 2010 , 363, 1727-33	59.2	622

160	Benign mesenchymal stromal cells in human sarcomas. <i>Clinical Cancer Research</i> , 2010 , 16, 5630-40	12.9	18
159	Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. <i>Clinical Cancer Research</i> , 2010 , 16, 4884-91	12.9	171
158	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 1693-703	59.2	3577
157	Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4985-95	2.2	171
156	Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. <i>Journal of Clinical Oncology</i> , 2010 , 28, 835-40	2.2	297
155	NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8 Suppl 2, S1-41; quiz S42-4	7.3	828
154	Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 2044-6	8.9	69
153	Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). <i>Cancer</i> , 2010 , 116, 2258-65	6.4	128
152	Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). <i>Leukemia Research</i> , 2010 , 34, 827-9	2.7	25
151	IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. <i>Journal of Pathology</i> , 2010 , 221, 300-7	9.4	67
150	A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO).. <i>Journal of Clinical Oncology</i> , 2010 , 28, 10004-10004	2.2	12
149	Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 10006-10006	2.2	45
148	Activity of sorafenib against desmoid tumor/deep fibromatosis (DT/DF).. <i>Journal of Clinical Oncology</i> , 2010 , 28, 10013-10013	2.2	3
147	Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 10021-10021	2.2	8
146	Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS) treated in clinical trials (CTs) versus expanded access programs (EAPs): A decade of experience with single-agent trabectedin (Tr).. <i>Journal of Clinical Oncology</i> , 2010 , 28, 10029-10029	2.2	2
145	Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2596-2596	2.2	23
144	Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3-3	2.2	76
143	Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. <i>Archives of Pathology and Laboratory Medicine</i> , 2010 , 134, 165-70	5	47

142	Effects of Long Term Imatinib on Bone Mineral Density In Patients with Chronic Myelogenous Leukemia (CML) or Gastrointestinal Stromal Tumor (GIST). <i>Blood</i> , 2010 , 116, 2276-2276	2.2	
141	KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. <i>Cancer Research</i> , 2009 , 69, 7175-9	10.1	208
140	Ifosfamide may be safely used in patients with end stage renal disease on hemodialysis. <i>Sarcoma</i> , 2009 , 2009, 575629	3.1	7
139	Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3148-53	2.2	184
138	A case of high-risk penile epithelioid hemangioendothelioma. <i>Nature Reviews Urology</i> , 2009 , 6, 223-7	5.5	8
137	Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3154-60	2.2	258
136	Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. <i>Clinical Cancer Research</i> , 2009 , 15, 5902-9	12.9	114
135	Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. <i>Clinical Cancer Research</i> , 2009 , 15, 6862-70	12.9	77
134	Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3133-40	2.2	461
133	Introduction: the 2008 European society for medical oncology international symposium on sarcomas and gastrointestinal stromal tumors. <i>Seminars in Oncology</i> , 2009 , 36, 289	5.5	
132	Sarcomas with spindle cell morphology. <i>Seminars in Oncology</i> , 2009 , 36, 324-37	5.5	20
131	Other targetable sarcomas. <i>Seminars in Oncology</i> , 2009 , 36, 358-71	5.5	12
130	Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. <i>Cancer Investigation</i> , 2009 , 27, 402-6	2.1	1
129	Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. <i>Lancet Oncology, The</i> , 2009 , 10, 1045-52	21.7	352
128	Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2009 , 373, 1097-104	40	1022
127	9401 Translocation-related sarcomas (TRS): a retrospective analysis of activity with trabectedin. <i>European Journal of Cancer, Supplement</i> , 2009 , 7, 590	1.6	2
126	9402 Efficacy and safety of trabectedin in soft tissue sarcoma (STS) are independent of patient age. <i>European Journal of Cancer, Supplement</i> , 2009 , 7, 590-591	1.6	2
125	GIST and Breast Cancer: 3 Case Reports and a Review of the Literature. <i>Current Cancer Therapy Reviews</i> , 2009 , 5, 100-104	0.4	0

124	A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. <i>Journal of Clinical Oncology</i> , 2009 , 27, 10503-10503	2.2	17
123	Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3509-3509	2.2	82
122	Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors. <i>Journal of Clinical Oncology</i> , 2009 , 27, e13510-e13510	2.2	7
121	A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. <i>American Journal of Pathology</i> , 2008 , 172, 1069-80	5.8	58
120	Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5352-9	2.3	583
119	Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008 , 19 Suppl 2, ii35-8	10.3	98
118	A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 282-4	9.7	145
117	A context dependent role for Wnt signaling in tumorigenesis and stem cells. <i>Cell Cycle</i> , 2008 , 7, 720-4	4.7	18
116	Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008 , 19 Suppl 2, ii89-93	10.3	88
115	A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. <i>Clinical Cancer Research</i> , 2008 , 14, 8191-7	12.9	131
114	Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. <i>Journal of Clinical Oncology</i> , 2008 , 26, 626-32	2.2	801
113	A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. <i>Clinical Cancer Research</i> , 2008 , 14, 6704-11	12.9	57
112	Molecular characterization of pediatric gastrointestinal stromal tumors. <i>Clinical Cancer Research</i> , 2008 , 14, 3204-15	12.9	211
111	DNA copy number analysis in gastrointestinal stromal tumors using gene expression microarrays. <i>Cancer Informatics</i> , 2008 , 6, 59-75	2.4	3
110	EBV-Associated Smooth Muscle Neoplasms: Solid Tumors Arising in the Presence of Immunosuppression and Autoimmune Diseases. <i>Sarcoma</i> , 2008 , 2008, 859407	3.1	30
109	Pediatric sarcomas occurring in adults. <i>Journal of Surgical Oncology</i> , 2008 , 97, 360-8	2.8	29
108	Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). <i>Cancer</i> , 2008 , 112, 608-15	6.4	375
107	Extraskelatal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy. <i>Cancer</i> , 2008 , 113, 3364-71	6.4	115

106	Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. <i>Genes Chromosomes and Cancer</i> , 2008 , 47, 853-9	5	284
105	Why do patients with low-grade soft tissue sarcoma die?. <i>Annals of Surgical Oncology</i> , 2008 , 15, 3550-60	3.1	50
104	Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. <i>Journal of Clinical Oncology</i> , 2008 , 26, 10502-10502	2.2	49
103	Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060. <i>Journal of Clinical Oncology</i> , 2008 , 26, 10531-10531	2.2	12
102	Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial. <i>Journal of Clinical Oncology</i> , 2008 , 26, 10533-10533	2.2	12
101	Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings. <i>Leukemia and Lymphoma</i> , 2007 , 48, 2071-4	1.9	6
100	Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2755-63	2.2	541
99	Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. <i>Annals of Surgical Oncology</i> , 2007 , 14, 134-42	3.1	90
98	Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis. <i>Cancer</i> , 2007 , 110, 2050-60	6.4	46
97	The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. <i>Nature Medicine</i> , 2007 , 13, 748-53	50.5	243
96	A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. <i>Digestive Diseases and Sciences</i> , 2007 , 52, 1964-72	4	75
95	Recent advances in therapy for gastrointestinal stromal tumors. <i>Current Oncology Reports</i> , 2007 , 9, 165-8	3.3	9
94	Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. <i>Clinical Cancer Research</i> , 2007 , 13, 170-81	12.9	101
93	Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. <i>Clinical Cancer Research</i> , 2007 , 13, 2643-50	12.9	189
92	Evidence-based recommendations for local therapy for soft tissue sarcomas. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1003-8	2.2	131
91	Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. <i>Cancer Research</i> , 2007 , 67, 6626-36	10.1	186
90	Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. <i>Clinical Cancer Research</i> , 2007 , 13, 4874-81	12.9	134
89	Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. <i>Annals of Surgery</i> , 2007 , 245, 347-52	7.8	235

88	Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. <i>Annals of Surgery</i> , 2007 , 246, 105-13	7.8	159
87	Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. <i>Oncologist</i> , 2007 , 12, 999-1006	7.6	80
86	Opportunities for improving the therapeutic ratio for patients with sarcoma. <i>Lancet Oncology</i> , 2007 , 8, 513-24	21.7	123
85	CYP3A4/5 and pharmacogenetics in patients with sarcoma - Authors Reply. <i>Lancet Oncology</i> , 2007 , 8, 668-9	21.7	
84	Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. <i>Journal of Clinical Investigation</i> , 2007 , 117, 3248-57	15.9	150
83	Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060). <i>Journal of Clinical Oncology</i> , 2007 , 25, 10001-10001	2.2	14
82	Analysis of toxicity in a phase II study of sorafenib in soft tissue sarcoma (STS). <i>Journal of Clinical Oncology</i> , 2007 , 25, 10061-10061	2.2	2
81	Gastrointestinal Stromal Tumors (GIST) and Their Management. <i>Gastrointestinal Cancer Research: GCR</i> , 2007 , 1, S81-4		1
80	NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST) Update of the NCCN Clinical Practice Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5, S-1-S-29	7.3	183
79	NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5 Suppl 2, S1-29; quiz S30	7.3	187
78	The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects. <i>Clinical Cancer Research</i> , 2006 , 12, 6203-4	12.9	23
77	Altered bone and mineral metabolism in patients receiving imatinib mesylate. <i>New England Journal of Medicine</i> , 2006 , 354, 2006-13	59.2	248
76	Management dilemmas due to a paratracheal follicular dendritic cell tumor. <i>Annals of Thoracic Surgery</i> , 2006 , 82, 1898-900	2.7	8
75	A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas. <i>Sarcoma</i> , 2006 , 2006, 15947	3.1	27
74	Future directions for immunotherapeutic intervention against sarcomas. <i>Current Opinion in Oncology</i> , 2006 , 18, 363-8	4.2	17
73	Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. <i>Journal of Clinical Oncology</i> , 2006 , 24, 9502-9502	2.2	50
72	Sirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 9503-9503	2.2	10
71	A putative tumor suppressor role for Wnt-signaling in sarcomagenesis. <i>Journal of Clinical Oncology</i> , 2006 , 24, 9507-9507	2.2	2

70	A SARC multicenter phase III study of gemcitabine (G) vs. gemcitabine and docetaxel (G+D) in patients (pts) with metastatic soft tissue sarcomas (STS). <i>Journal of Clinical Oncology</i> , 2006 , 24, 9514-9514 ^{2,2}	2.2	11
69	A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. <i>Journal of Clinical Oncology</i> , 2006 , 24, 9515-9515	2.2	7
68	DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). <i>Journal of Clinical Oncology</i> , 2006 , 24, 9522-9522	2.2	15
67	A phase I trial of doxorubicin and flavopiridol in soft tissue sarcoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 9523-9523	2.2	1
66	Pharmacodynamic case study of sunitinib/SU11248 in a gastrointestinal stromal tumor patient: Evidence toward a mechanism of effect. <i>Journal of Clinical Oncology</i> , 2006 , 24, 9526-9526	2.2	1
65	Mechanisms of sarcomagenesis. <i>Hematology/Oncology Clinics of North America</i> , 2005 , 19, 427-49, v	3.1	19
64	Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. <i>Annals of Oncology</i> , 2005 , 16, 566-78	10.3	518
63	Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7135-42	2.2	218
62	De novo osteogenic sarcoma in patients older than forty: benefit of multimodality therapy. <i>Clinical Orthopaedics and Related Research</i> , 2005 , 438, 110-5	2.2	33
61	Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. <i>Journal of Pediatric Hematology/Oncology</i> , 2005 , 27, 179-87	1.2	207
60	A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. <i>Cancer Journal (Sudbury, Mass.)</i> , 2005 , 11, 241-7	2.2	290
59	A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. <i>Cancer</i> , 2005 , 103, 1431-4	3.4	66
58	Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5484-92	2.2	152
57	Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. <i>Clinical Cancer Research</i> , 2005 , 11, 4182-90	12.9	668
56	Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1875-84	2.2	102
55	Metastatic colon cancer to the ovaries in a Krukenberg-like pattern. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5255-6	2.2	3
54	Bluish papule in a middle-aged man. <i>Archives of Dermatology</i> , 2005 , 141, 1595-600		1
53	Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). <i>Journal of Clinical Oncology</i> , 2005 , 23, 9011-9011	2.2	66

52	Incidence and reasons for dose modification of standard-dose vs. high-dose imatinib mesylate (IM) in the Phase III Intergroup Study S0033 of patients (pts) with unresectable or metastatic gastrointestinal stromal tumor (GIST). <i>Journal of Clinical Oncology</i> , 2005 , 23, 9032-9032	2.2	2
51	Fighting Cancer Through the Study of Sarcomas. <i>American Scientist</i> , 2005 , 93, 414	2.7	2
50	Molecular profiling of liposarcoma subtypes. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9016-9016	2.2	
49	Role of chemotherapy in patients with soft tissue sarcomas. <i>Expert Review of Anticancer Therapy</i> , 2004 , 4, 229-36	3.5	18
48	Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1480-90	2.2	247
47	Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. <i>Clinical Cancer Research</i> , 2004 , 10, 1250-4	12.9	91
46	Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4567-74	2.2	128
45	Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. <i>Annals of Oncology</i> , 2004 , 15, 1667-72	10.3	150
44	Gastrointestinal Stromal Tumors Respond to Tyrosine Kinase-targeted Therapy. <i>Current Treatment Options in Gastroenterology</i> , 2004 , 7, 13-17	2.5	18
43	Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. <i>Clinical Cancer Research</i> , 2004 , 10, 3282-90	12.9	175
42	The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. <i>Annals of Surgery</i> , 2004 , 240, 686-95; discussion 695-7	7.8	119
41	SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). <i>Journal of Clinical Oncology</i> , 2004 , 22, 3001-3001	2.2	35
40	Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9001-9001	2.2	8
39	Activity of imatinib mesylate in desmoid tumors: Interim analysis of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9013-9013	2.2	4
38	Impact of ifosfamide-based chemotherapy on survival in patients with primary extremity synovial sarcoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9017-9017	2.2	4
37	Activity of gemcitabine plus docetaxel in leiomyosarcoma (LMS) and other histologies: Report of an expanded phase II trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9010-9010	2.2	2
36	Activity of imatinib mesylate in desmoid tumors: Interim analysis of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9013-9013	2.2	4
35	Impact of ifosfamide-based chemotherapy on survival in patients with primary extremity synovial sarcoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9017-9017	2.2	2

34	NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2004 , 2 Suppl 1, S-1-26; quiz 27-30	7.3	40
33	Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 8862-7	11.5	168
32	Therapeutic impact of ET-743 (Yondelis; trabectedin), a new marine-derived compound, in sarcoma. <i>Current Opinion in Orthopaedics</i> , 2003 , 14, 419-428		8
31	Immunity against soft-tissue sarcomas. <i>Current Oncology Reports</i> , 2003 , 5, 282-7	6.3	9
30	Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. <i>Cancer</i> , 2003 , 98, 832-40	6.4	87
29	Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. <i>American Journal of Pathology</i> , 2003 , 163, 691-700	5.8	185
28	The intricate interplay among body weight, stress, and the immune response to friend or foe. <i>Journal of Clinical Investigation</i> , 2003 , 111, 183-185	15.9	29
27	Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. <i>Current Problems in Surgery</i> , 2003 , 40, 144-93	2.8	20
26	Sarcomas of Soft Tissue 2002 , 197-203		
25	Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. <i>International Journal of Cancer</i> , 2002 , 100, 623-6	7.5	225
24	Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 309-19	3.5	55
23	Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2824-31	2.2	594
22	Multidisciplinary management of soft-tissue sarcomas. <i>Cancer Investigation</i> , 2002 , 20, 818-24	2.1	4
21	A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. <i>Oncologist</i> , 2002 , 7, 531-8	5.7	44
20	Cascades of transcriptional induction during human lymphocyte activation. <i>European Journal of Cell Biology</i> , 2001 , 80, 321-8	6.1	33
19	Sarcoma. <i>Oncologist</i> , 2001 , 6, 333-7	5.7	3
18	Soft tissue sarcoma as a model disease to examine cancer immunotherapy. <i>Current Opinion in Oncology</i> , 2001 , 13, 270-4	4.2	22
17	A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. <i>Nature Medicine</i> , 2000 , 6, 991-7	50.5	1675

16	Role of interleukin 12 and costimulators in T cell energy in vivo. <i>Journal of Experimental Medicine</i> , 1997 , 186, 1119-28	16.6	78
15	Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors. <i>Journal of Medicinal Chemistry</i> , 1997 , 40, 1955-68	8.3	33
14	Tumor-specific cell surface expression of the-KDEL containing, endoplasmic reticular heat shock protein gp96. <i>International Journal of Cancer</i> , 1996 , 69, 340-9	7.5	141
13	O-alkylcarboxylate oxime and N-hydroxyurea analogs of substituted indole leukotriene biosynthesis inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1996 , 6, 1547-1552	2.9	11
12	Mapping of the genes for human endoplasmic reticular heat shock protein gp96/grp94. <i>Somatic Cell and Molecular Genetics</i> , 1993 , 19, 73-81		23
11	Stress-induced proteins in immune response to cancer. <i>Current Topics in Microbiology and Immunology</i> , 1991 , 167, 109-23	3.3	120
10	Human homologue of murine tumor rejection antigen gp96: 5 α regulatory and coding regions and relationship to stress-induced proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 5658-62	11.5	121
9	Potent, low molecular weight renin inhibitors containing a C-terminal heterocycle: hydrogen bonding at the active site. <i>Journal of Medicinal Chemistry</i> , 1990 , 33, 1582-90	8.3	23
8	New inhibitors of renin that contain novel phosphostatine Leu-Val replacements. <i>Journal of Medicinal Chemistry</i> , 1990 , 33, 534-42	8.3	93
7	Evaluation of the rate constant for the reaction OH+H ₂ CO: Application of modeling and sensitivity analysis techniques for determination of the product branching ratio. <i>Journal of Chemical Physics</i> , 1989 , 91, 4088-4097	3.9	37
6	An iterative synthesis of radiolabelled polyethylene glycol oligomers. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1989 , 27, 1437-1450	1.9	3
5	Divalent cations regulate glucagon binding. Evidence for actions on receptor-Ns complexes and on receptors uncoupled from Ns. <i>Biochemistry</i> , 1988 , 27, 1111-6	3.2	9
4	Optimization and in vivo evaluations of a series of small, potent, and specific renin inhibitors containing a novel Leu-Val replacement. <i>Journal of Medicinal Chemistry</i> , 1987 , 30, 2137-44	8.3	35
3	The enantio- and diastereoselective synthesis of the first phospho-statine derivative. <i>Tetrahedron Letters</i> , 1986 , 27, 2337-2340	2	29
2	Lyman-alpha. photometry: curve of growth determination, comparison to theoretical oscillator strength, and line absorption calculations at high temperature. <i>The Journal of Physical Chemistry</i> , 1985 , 89, 4815-4821		31
1	MEDICAL ONCOLOGY OF SOFT TISSUE SARCOMAS1070-1082		0